PMID- 35961417
OWN - NLM
STAT- MEDLINE
DCOM- 20220912
LR  - 20220912
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 625
DP  - 2022 Sep 25
TI  - A review on the latest developments of mesoporous silica nanoparticles as a 
      promising platform for diagnosis and treatment of cancer.
PG  - 122099
LID - S0378-5173(22)00653-6 [pii]
LID - 10.1016/j.ijpharm.2022.122099 [doi]
AB  - Cancer is the second cause of human mortality after cardiovascular disease around 
      the globe. Conventional cancer therapies are chemotherapy, radiation, and 
      surgery. In fact, due to the lack of absolute specificity and high drug 
      concentrations, early recognition and treatment of cancer with conventional 
      approaches have become challenging issues in the world. To mitigate against the 
      limitations of conventional cancer chemotherapy, nanomaterials have been 
      developed. Nanomaterials exhibit particular properties that can overcome the 
      drawbacks of conventional therapies such as lack of specificity, high drug 
      concentrations, and adverse drug reactions. Among nanocarriers, mesoporous silica 
      nanoparticles (MSNs) have gained increasing attention due to their well-defined 
      pore size and structure, high surface area, good biocompatibility and 
      biodegradability, ease of surface modification, and stable aqueous dispersions. 
      This review highlights the current progress with the use of MSNs for the delivery 
      of chemotherapeutic agents for the diagnosis and treatment of cancer. Various 
      stimuli-responsive gatekeepers, which endow the MSNs with on-demand drug 
      delivery, surface modification strategies for targeting purposes, and 
      multifunctional MSNs utilized in drug delivery systems (DDSs) are also addressed. 
      Also, the capability of MSNs as flexible imaging platforms is considered. In 
      addition, physicochemical attributes of MSNs and their effects on cancer therapy 
      with a particular focus on recent studies is emphasized. Moreover, major 
      challenges to the use of MSNs for cancer therapy, biosafety and cytotoxicity 
      aspects of MSNs are discussed.
CI  - Copyright (c) 2022 The Author(s). Published by Elsevier B.V. All rights reserved.
FAU - Ahmadi, Fatemeh
AU  - Ahmadi F
AD  - Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of 
      Medical Sciences, Sari, Iran.
FAU - Sodagar-Taleghani, Arezoo
AU  - Sodagar-Taleghani A
AD  - Department of Petroleum and Chemical Engineering, Science and Research Branch, 
      Islamic Azad University, Tehran, Iran; Young Researchers and Elite Club, Science 
      and Research Branch, Islamic Azad University, Tehran, Iran.
FAU - Ebrahimnejad, Pedram
AU  - Ebrahimnejad P
AD  - Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of 
      Medical Sciences, Sari, Iran; Pharmaceutical Sciences Research Center, 
      Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, 
      Iran. Electronic address: pebrahimnejad@mazums.ac.ir.
FAU - Pouya Hadipour Moghaddam, Seyyed
AU  - Pouya Hadipour Moghaddam S
AD  - Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt 
      Lake City, UT 84112, USA; Electrical and Computer Engineering, University of 
      Utah, Salt Lake City, UT 84112, USA.
FAU - Ebrahimnejad, Farzam
AU  - Ebrahimnejad F
AD  - Paul G. Allen School of Computer Science and Engineering, University of 
      Washington, Seattle, USA.
FAU - Asare-Addo, Kofi
AU  - Asare-Addo K
AD  - Department of Pharmacy, School of Applied Sciences, University of Huddersfield, 
      Huddersfield, UK.
FAU - Nokhodchi, Ali
AU  - Nokhodchi A
AD  - Pharmaceutics Research Laboratory, School of Life Sciences, University of Sussex, 
      Brighton, UK; Lupin Pharmaceutical Research Inc., Coral Springs, FL, USA. 
      Electronic address: a.nokhodchi@sussex.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220810
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Drug Carriers)
RN  - 7631-86-9 (Silicon Dioxide)
SB  - IM
MH  - Drug Carriers/chemistry
MH  - Drug Delivery Systems/methods
MH  - Humans
MH  - *Nanoparticles/chemistry
MH  - *Neoplasms/diagnosis/drug therapy
MH  - Porosity
MH  - Silicon Dioxide/chemistry
OTO - NOTNLM
OT  - Cancer therapy
OT  - Diagnostics
OT  - Drug delivery
OT  - Mesoporous silica
OT  - Nanoparticles
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/08/13 06:00
MHDA- 2022/09/14 06:00
CRDT- 2022/08/12 19:23
PHST- 2022/03/22 00:00 [received]
PHST- 2022/07/24 00:00 [revised]
PHST- 2022/08/05 00:00 [accepted]
PHST- 2022/08/13 06:00 [pubmed]
PHST- 2022/09/14 06:00 [medline]
PHST- 2022/08/12 19:23 [entrez]
AID - S0378-5173(22)00653-6 [pii]
AID - 10.1016/j.ijpharm.2022.122099 [doi]
PST - ppublish
SO  - Int J Pharm. 2022 Sep 25;625:122099. doi: 10.1016/j.ijpharm.2022.122099. Epub 
      2022 Aug 10.